Developing innovative peptide drugs to fight specialist diseases
P140 peptide innovation
Unique mechanism of action
Lupuzor’s™ / P140’s unique mechanism of action involves modulating the activation of auto-reactive T-cells. Other attempts to modulate the immune response in SLE have been done further downstream in the immune cascade (see diagram above), most notably in the regulation of B-cells with little success.
However, in targeting upstream T-cell activation, LupuzorTM presents a novel approach in modulating this unwelcome autoimmune reaction.
This targeted approach marks a paradigm shift in treating autoimmune disease. Instead of shutting down otherwise healthy immune responses the T-cells are suppressed, leaving the immune system deleted from unwanted deleterious cells but intact as normal, beneficial immune cells are concerned.
Near term: Lupus • CIDP
Long term: Asthma • Gout
Taking old drugs and adapting them to develop a new more effective drug
Our proprietary peptide technology lends itself well to taking established products like Vancomycin and greatly improving their pharmacology.
Increased antibiotic and anti-fungal resistance is one of the biggest threats to global health, cost and mortality (WHO).
Despite the obvious threats, anti-infectives is a therapy area that attracts one of the lowest R&D spends in the biopharma industry: 80% of biopharma are focused on oncology and orphan drugs, while drug development for anti-infectives is shorter and less costly.
A significant problem in immunosuppressed patient are serious fungal infections.
Sepsis • Lower respiratory tract
Skin • Bone infections • MRSA